The over -the -counter supplement could prevent heart disease in type 2 diabetic patients

A cheaply over -the -counter cheap supplement could maintain the key to prevent heart failure in people with type 2 diabetes, according to research presented on Tuesday at British conference Cardiovascular Society in Manchester.

The study revealed that patients with diabetes who took daily mitoquinone, an antioxidant widely available, as well as their standard treatment had a healthier heart after four months than those who did not give the supplement. Mitoquinone was able to reverse the first signs of heart failure linked to diabetes during the study.

Dr. Henry Procter, clinical researcher at the University of Leeds and principal author of the study, said: “These encouraging results are a sign that mitoquinone could keep the hearts healthier longer in people with diabetes. If the study continued longer, it is likely that we would have started to see differences in more serious heart health indicators between the group with the group without.”

“We hope that a larger study will continue to demonstrate the advantages of this antioxidant, and that one day, diabetic patients soon can be prescribed to help prevent heart failure before it affects their lives.”

It is estimated that more than 5.8 million people in the United Kingdom suffer from diabetes, a top of all time, with approximately 90% having a type 2. This number should continue to increase, and type 2 diabetic patients are up to five times more likely to develop heart failure than the rest of the population. Once a diabetes patient is diagnosed with heart failure, it is three times more likely to die in the next five years.

Diabetes causes problems with the way the body, including the heart, the processes and uses energy – its metabolism. This can cause stress and damage to cardiac muscle cells, which, over time, can cause the heart stiffening and be unable to pump blood well, ultimately at the point of heart failure.

Mitoquinone is an antioxidant supplement which is supposed to protect cells from this stress and metabolic damage. It is often sold online at amateur athletes And others, as manufacturers, claim that it can improve cellular energy levels and support healthy aging. However, so far, there has been very little clinical data on its effectiveness to protect the hearts of diabetic patients.

The researchers found that after four months of mitoquinone, the hearts of diabetic patients were able to treat and use energy 15% more effectively when they had not been. Improvements were also observed during the exercise. In addition to that, the heart muscles of the Mitoquinone group were able to relax more quickly. These are all signs that the first stress and stressful indicators in the heart of this group had been reversed.

The team recruited 70 people with type 2 diabetes through Leeds. People who already had heart disease were not included in the study. Cardiac tests and scanners were carried out before and after a period of four months when half of the participants took 40 mg of mitoquinone tablets daily as well as their normal diabetes treatments, and the other half had their normal treatment.

The Mitoquinone group saw an inversion in the first signs of metabolic stress. The standard treatment group has not seen the same changes. After the four months, none of the study patients had developed dangerous cardiac symptoms or seen changes in their diabetes control. There was no major side effects to take mitoquinone.

The team now plans to direct a larger mitoquinone test in diabetic patients, to collect more evidence than the supplement could protect hearts and prevent heart failure Over time. If the results of other studies are positive, they hope that diabetic patients could one day be prescribed with mitoquinone to keep their hearts healthier longer.

Professor Bryan Willians, in chief scientific and doctor of the British Heart Foundation, said: “This study presents intriguing initial results. It is still very early for this research and the results will have to be confirmed in a larger -scale trial. The study perfectly demonstrates why it is so important to continue to support research and seek solutions in a wide variety of places in Cardia.”

Supplied by the British Heart Foundation